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Multiple myeloma (MM), a B-cell malignancy with accumulation of clonal, malignant plasma cells in the bone marrow, is the second most common haematological malignancy affecting over 20 000 patients each year in the United States. 1 Although, allogeneic bone marrow transplantation is still performed at the expense of a significant treatment-related toxicity, the graft-versus-myeloma effect has demonstrated that MM cells can be eliminated by effector T cells, and moreover that this results in higher remission rates and even cures. 2 By targeting antigens that are exclusively expressed by MM cells, the efficiency and safety of myeloma- Figure 1 . In vitro stimulation of sorted CD45RA À CD25 high þ / À CD4 þ T cells and definition of restriction elements. CD4 þ CD45RA À and CD4 þ CD45RA À CD25 high À fractions were sequentially sorted out of CD8 þ T-cell-depleted peripheral blood mononuclear cells (PBMCs) from three CT7
þ MM patients and stimulated with the CD4 À CD8 À APC fraction pulsed with either peptide pools (ZH-259; (a) left and ZH-590; (b) left) or previously identified peptide aa 941-960 for ZH-683 (c, left). On days 18-21, cells were harvested and rechallenged using autologous T cell-antigen presenting cells (T-APCs) pulsed with the relevant pool/peptide and a control pool/peptide. Interferon (IFN)-g was measured in a standard intracellular cytokine stain (ICS) assay. To define restriction elements and minimal epitopes CT7-specific CD4 þ T-cell clones were stimulated with the relevant peptide in the presence of blocking antibodies to HLA-DR, HLA-DP or HLA-DQ. Partially matched cell lines pulsed with cognate peptides were used to define the exact restriction allele (a-c, right). One representative experimental replicate out of three is shown.
Accepted article preview online 1 February 2013; advance online publication, 22 February 2013 specific immunotherapy can be drastically improved. 3 Among the currently known tumour antigens, cancer-testis (CT) antigens represent one of the most relevant groups for the development of cancer immunotherapy because of their restricted expression in germ line and cancer tissues and their broad immunogenicity. 4 Naturally occurring immune responses against CT antigens, that is, NY-ESO-1 and MAGE-A family of antigens have been previously described in MM patients. 5 These responses were found frequently and often correlated with disease burden.
MAGE-C1/CT7 is the most frequently expressed CT antigen in MM lesions being found in 450% of cases. 6, 7 We have described previously that CT7 is able to elicit a specific humoral immune response in a proportion of stages I-III MM patients. 8 Although, the presence of CT7-specific T cells in bone marrow of MM patients has been described, this study did not discriminate between CD4
þ and CD8 þ T-cell responses, nor did it identify epitopes or exclude the possibility of in vitro priming. 9 To assess the presence of a specific memory T-cell response, we analysed naturally occurring CT7-specific CD4 þ T cells in peripheral blood mononuclear cell from 18 MM patients with CT7 þ bone marrow lesions by in vitro stimulation with pools of 20-mer overlapping peptides (10 aa overlap) spanning the entire CT7 sequence. All samples have been taken from patients after they have signed a written consent form according to the Declaration of Helsinki. In vitro stimulation assays were performed with fluorescenceactivated cell sorted CD45RA
-(memory) CD4 þ T-cell fraction from CD8 þ T-cell-depleted peripheral blood mononuclear cell to exclude the possibility that the detected CD4 þ T cells resulted from in vitro primed naive cells. Methods and materials used in this study are analogous to the ones used in our previous study. 10 In addition, to assess whether T regulatory cells (Tregs) preclude the functional detection of CT7-specific CD4 þ T-cell responses in MM patients, the CD45RA À CD4 þ T-cell fraction was either depleted of CD25 high Treg cells by further sorting or left alone. We detected CT7-specific memory CD4 þ T cells in 3 out of 18 MM patients (Figures 1a and b , left panels; patients ZH-259 and ZH-590, respectively). Only one patient (ZH-683; Figure 1c , left panel) showed a detectable CT7-specific CD4 þ T-cell response in the presence of Tregs. These results show that Tregs control CD4 þ CT7-specific T-cell responses in MM, which is in agreement with our previous findings in melanoma patients. 10 Furthermore, our data suggest that the immunogenicity of tumour-associated antigens may often be underestimated when tested without depleting Treg. Several reports have described a correlation between increased Treg numbers and disease burden in MM patients. 11, 12 In addition, a study using mouse models demonstrated that the use of low-dose cyclophosphamide acts by selectively inducing apoptosis of Tregs, which in turn resulted in prolonged disease-free survival of tumour-bearing mice. 13 From the three patients with CT7-specific T-cell response, we could see that at the time of blood collection, patient ZH-590 had active disease (initial Stage III based on International Staging System (ISS) and III on Durie Salmon staging system (DSS)), patient ZH-259 had a stable disease with partial remission (initial stage I on ISS and III on DSS) and patient ZH-683 had progressive disease (initial stage I on ISS and III on DSS). Previously published report found naturally occurring MAGE-A-specific CD4 þ T-cell response predominantly in monoclonal gammopathy of undetermined significance (MGUS) patients.
14 One reason for this discrepancy could be that CT7 is prominently expressed in later stages of MM while MAGE-A is expressed consistently throughout MGUS and MM. 7 The unavailability of peripheral blood samples from MGUS patients precludes any further conclusions.
Single interferon-g-producing cells were single cell sorted on a FACSAria machine (BD, San Jose, CA, USA) from three CT7-specific To demonstrate that CT7-specific CD4 þ T-cell clones recognize naturally processed CT7, we pulsed monocyte-derived mature dendritic cells (DCs) from the same patients with recombinant CT7 Figure 2 . CT7-specific CD4 þ T-cell clones recognize naturally processed antigen. CT7-specific CD4 þ T-cell clones from ZH-683, ZH-590 and ZH-259 were incubated with autologous mature dendritic cells pulsed with 10 mg/ml recombinant CT7 protein or irrelevant RAB38 protein for 16 h followed by interferon (IFN)-g ICS. One representative experimental replicate out of two is shown (a). Partially matched cell lines, as in Figures 1 (a-c, right) , pulsed with titrated amounts cognate peptides were used to measure the exact peptide affinity of CT7-specific CD4 T-cell clones (b). protein produced as previously described. 8 All three clones (CT7/ 259/2; CT7/590/7; CT7/683/9) recognized CT7-pulsed DC, thus demonstrating that the peptides recognized by the CD4 þ T-cell clones contain naturally processed epitopes (Figure 2a) . Peptide affinity was measured in a classic titration assay demonstrating that all three clones have a low to intermediate affinity for their respective 20mer peptide (Figure 2b ).
High number of overlapping pooled peptides resulting from the large CT7 size (1142 aa) proved to be an inadequate antigen delivery system to analyse CT7-specific CD8 þ T cells especially when the patient's material is limited. 10 However, since described CT7-specific CD4 þ T-cell responses are clearly of Th1 type it is probable that a Cytotoxic T-Lymphocyte (CTL) response would ensue. Recently, a study identified CT7-specific, HLA-A2 restricted CD8 þ T cells, in peripheral blood mononuclear cell from healthy donors. These CD8 þ T cells were able to recognize CT7 þ MM cell line albeit they have not been confirmed in MM patients. 15 Interestingly, the three patients with CT7-specific CD4 þ T-cell response had a, previously described, CT7-specific humoral immune response 8 giving further evidence that there is a broad immune response towards CT7 in MM patients and that CT7-specific CD4 þ T cells in MM perform their classical helper role in promoting an anti-tumour immune response.
Taken together these findings show, for the first time, that MM patients develop T-cell immune responses towards CT7, which is the most frequently expressed CT antigen in MM. Therefore, targeting CT7 with simultaneous use of immune suppression antagonists is of great promise for MM immunotherapy.
Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia Chronic lymphocytic leukemia (CLL) is characterized by the expansion of monoclonal, mature CD5 þ /CD23 þ B cells. 1 In addition, small lymphocytic lymphoma (SLL) shares the biological characteristics of CLL; however, it is distinguished from CLL based on not exceeding 5000 clonal B-lymphocytes per ml. Here we use the term CLL throughout to denote both CLL and SLL.
A role of antigen signaling in the pathogenesis of CLL has been inferred from the observation that CLL cells use a restricted repertoire of immunoglobulin heavy chain variable (IGHV) genes, which encode antigen binding domains of the B-cell receptor Accepted article preview online 14 February 2013; advance online publication, 1 March 2013
